Edwards Lifesciences Co. (NYSE:EW) Holdings Increased by Banque Pictet & Cie SA

Banque Pictet & Cie SA increased its stake in Edwards Lifesciences Co. (NYSE:EW) by 106.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 156,968 shares of the medical research company’s stock after acquiring an additional 80,851 shares during the period. Banque Pictet & Cie SA’s holdings in Edwards Lifesciences were worth $11,620,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in EW. V Square Quantitative Management LLC boosted its stake in Edwards Lifesciences by 2.3% during the fourth quarter. V Square Quantitative Management LLC now owns 15,374 shares of the medical research company’s stock valued at $1,138,000 after buying an additional 348 shares in the last quarter. Bogart Wealth LLC lifted its holdings in Edwards Lifesciences by 38.2% in the 4th quarter. Bogart Wealth LLC now owns 92,768 shares of the medical research company’s stock valued at $6,868,000 after acquiring an additional 25,657 shares during the last quarter. Asset Management One Co. Ltd. boosted its position in shares of Edwards Lifesciences by 1.0% during the 4th quarter. Asset Management One Co. Ltd. now owns 241,818 shares of the medical research company’s stock valued at $18,294,000 after purchasing an additional 2,426 shares in the last quarter. Avestar Capital LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $203,000. Finally, Clarity Capital Partners LLC raised its holdings in shares of Edwards Lifesciences by 21.5% in the 4th quarter. Clarity Capital Partners LLC now owns 11,142 shares of the medical research company’s stock worth $825,000 after purchasing an additional 1,973 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.2 %

Shares of NYSE:EW opened at $75.96 on Friday. The company’s fifty day moving average is $72.51 and its 200-day moving average is $69.36. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a market capitalization of $44.80 billion, a PE ratio of 10.96, a P/E/G ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities research analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. This trade represents a 12.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,750 shares of company stock valued at $1,564,255 over the last 90 days. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

EW has been the topic of several research reports. The Goldman Sachs Group upped their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Finally, Piper Sandler raised their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.